Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with significant health benefits.

Orfoglipron was associated with improved glycemic control and weight reduction among patients with early-stage type 2 diabetes.

In myasthenia gravis, complement plays a big role in what happens to the muscle end of the neuromuscular junction, explains ...

Ultragenyx Pharmaceuticals RARE announced that the FDA has granted the Breakthrough Therapy designation to its ...

The Food and Drug Administration has approved Harliku (nitisinone) for the reduction of urine homogentisic acid in adult patients with alkaptonuria.

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...